Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis.

Rao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, Hu Y, Song B, Jiang Z, Ge Z, Liu X, Li C, Chen S, Ye J, Huang Z, Lu Y. · 2021

Read Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. by Rao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, Hu Y, Song B, Jiang Z, Ge Z, Liu X, Li C, Chen S, Ye J, Huang Z, Lu Y. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8158032.txt.

Introduction

Rao and co-authors test a gut bacterium as a treatment for fatty liver disease in mice. Akkermansia muciniphila has shown promise against obesity and diabetes. The team fed mice a high-fat, high-cholesterol diet to induce the liver disease.

The authors report that the bacterium reversed liver fat build-up, inflammation, and injury. Benefits lasted after long-term withdrawal, though antibiotics weakened them slightly. Treatment raised mitochondrial oxidation and bile acid metabolism along the gut-liver axis. It also eased oxidative stress. The proposed path runs through L-aspartate metabolism. The results point to the gut-liver axis as a treatment target.

Catalog record

CREATORRao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, Hu Y, Song B, Jiang Z, Ge Z, Liu X, Li C, Chen S, Ye J, Huang Z, Lu Y.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE73 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8158032

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis By Yong Rao, Zhiqi Kuang, Chan Li, Shiyao Guo, Yaohao Xu, Dandan Zhao, Yutao Hu, Bingbing Song, Zhi Jiang, Zhenhuang Ge, Xiyuan Liu, Chengdao Li Published in: Gut Microbes DOI: 10.1080/19490976.2021.1927633 ABSTRACT ABSTRACT The gut bacterium Akkermansia muciniphila has been increasingly recognized for its therapeutic potential in treating metabolic disorders, including obesity, diabetes, and metabolicdysfunction-associated fatty liver disease (MAFLD). However, its underlying mechanism involved in its well-known metabolic actions needs further evaluation. The present study explored the therapeutic effect and mechanism of A. muciniphila in intervening MAFLD by using a high-fat and high-cholesterol (HFC) diet induced obese mice model. Mice treated with A. muciniphila efficiently reversed MAFLD in the liver, such as hepatic steatosis, inflammatory, and liver injury. These therapeutic effects persisted after long-term drug withdrawal and were slightly weakened in the antibiotics-treated obese mice. A. muciniphila treatment efficiently increased mitochondrial oxidation and bile acid metabolism in the gut-liver axis, ameliorated oxidative stress-induced cell apoptosis in gut, leading to the reshaping of the gut microbiota composition. These metabolic improvements occurred with increased L-aspartate levels in the liver that transported from the gut. The administration of L-aspartate in vitro or in mice displayed the similar beneficial metabolic effects mentioned above and efficiently ameliorated MAFLD. Together, these data indicate that the anti-MAFLD activity of A. muciniphila correlated with lipid oxidation and improved gut–liver interactions through regulating the metabolism of L-aspartate. A. muciniphila could be a potential agent for clinical intervention in MAFLD. INTRODUCTION Metabolicdysfunction-associated fatty liver disease (MAFLD, previously known as Nonalcohol fatty liver disease, NAFLD) is defined as a wide spectrum of liver diseases, including simple steatosis (NAFL), nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis, and even hepatocellular carcinoma (HCC).1,2 MAFLD has become a leading liver disease, with a prevalence of 22–29% in adults worldwide, greater than 75% of whom are overweight and obese.3 However, to date, no approved pharmacological agents are available for MAFLD treatment. MAFLD is a metabolic syndrome characterized by heavy lipid accumulation, and associated with oxidative stress, lobular inflammation, apoptosis, and a certain degree of fibrosis progressively in clinical hepatic pathologic findings.4 Among these manifestations, hepatic steatosis serves as the first initiator (first hit), displaying aggressive injury to hepatocytes, and followed by multiple hits including oxidative stress, mitochondrial dysfunction and degeneration, and apoptosis, which lead to fibrosis in the liver.5 Our previous and recent studies have demonstrated that increasing hepatic lipid oxidation by pharmacologic treatment or gene editing is an efficacious approach to combat MAFLD by decreasing the lipid content and ameliorating progressive oxidation stress, lipotoxicity, inflammation and fibrosis,6–8 which agree with the recommendations of anti-NASH drug development.9 The gut microbiota is a virtual metabolic and endocrine organ that comprises approximately 1014 microbial cells inside the gut.10 These microorganisms are associated with the regulation of host metabolism, and immunity via their abundant metabolites, such as short-chain fatty acids (SCFAs) and amino acids.11,12 Recently, the gut microbiome has drawn extensive attention and served as a therapeutic approach in combating MAFLD.13,14 Akkermansia muciniphila, represents 1 to 5% of the microbial community in humans, and is considered to be a next-generation beneficial microbes.15 Treatment with A. muciniphila has been shown to protect metabolic disorders, including fat-mass gain, metabolic endotoxemia, adipose tissue inflammation, and insulin resistance.16–18 Also, several studies have revealed that A. muciniphila is an efficacious agent to prevent the worsening of metabolic disorders such as obesity.16,18,19 Additionally, several studies have shown the efficacious treatment of A. muciniphila in combating MAFLD in vivo by either direct treatment with A. muciniphila or enrichment of its abundance in gut through diet or drugs interventions .20–22 Although the beneficial metabolic effects of A. muciniphila have been well documented, however, to date, the detailed mechanism underlying the therapeutic ability of A. muciniphila is incompletely understood. Therefore, the first aim of the present study was to evaluate the therapeutic properties of A. muciniphila in treating MAFLD in an obese mice model induced by high-fat and high-cholesterol (HFC) diets, which well mimics the humans daily diet and is critical for inducing hepatocyte injury and driving the development of fatty liver-associated disease.23 Our second aim was to investigate the molecular mode of action of A. muciniphila by identifying the significant metabolites correlated with MAFLD treatment. This was carried out by performing hepatic metabolomics analysis of the liver samples from A. muciniphila‐treated mice, in terms of the important pathological pathways leading to MAFLD and by relevant intervention studies in cell models. Our data revealed that mice treated with A. muciniphila efficiently increased lipid oxidation and bile acid metabolism, thus maintaining the integrity of the gut barrier and reshaping the gut microbiota composition. These beneficial metabolic effects occurred with increased levels of L-aspartate in the liver that transported from the gut. Moreover, gavage of L-aspartate in mice directly increased energy expenditure and ameliorated MAFLD. RESULTS Gavage of A. muciniphila attenuated MAFLD in obese mice Previous studies have shown that the gavage of A. muciniphila reshapes the gut microbiota composition in mice.24,25 In present study, we examined the gut microbiota composition in the feces of HFC mice with or without administration of A. muciniphila. Two distinguished clusters corresponding to the HFC mice and A. muciniphila-treated HFC mice revealed substantial differences in the microbial community structure between the groups (Figure S1A). Gavage of A. muciniphila in the mice increased the richness and diversity of gut microbiota by α-diversity analysis [indicated by observed operational taxonomic units (OTUs) and Shannon index] (Figure S1B) and improved the microbial community structure (Figure S1C-D). Notably, A. muciniphila was identified as one of the distinguished microbiota components by LEfSe analysis (p = .0096; Figure S1E). We then evaluated the therapeutic effect of A. muciniphila in treating MAFLD in an obese mouse model induced by HFC diet feeding (Figure 1a). Compared with the HFC group mice, mice treated with A. muciniphila efficiently increased the abundance of A. muciniphila in the gut by 20 folds compared with that in HFC mice by quantitative polymerase chain reaction (qPCR) (Figure 1b). This activity led to decreased mouse body weight, as indicated by an approximately 20.8% body weight reduction in A. muciniphila-treated HFC mice after 6 weeks of treatment (Figure 1c). Intriguingly, A. muciniphila treatment efficiently attenuated hepatic steatosis in HFC mice indicated by decreased hepatic TG (Figure 1d). Diacylglycerol (DAG) is a representative intermediate of lipid metabolism that induces activation of oxidative stress and displays toxicity to hepatocytes, leading to apoptosis and liver injury in vivo.26 Notably, treatment with A. muciniphila in obese mice markedly decreased the DAG levels in the liver (Figure 1e). Determination of plasma levels of liver-specific enzymes revealed that A. muciniphila significantly ameliorated liver injury in HFC mice, as indicated by decreased levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) (Figure 1f). Additionally, pathologic examination further confirmed the therapeutic potency of A. muciniphila in ameliorating all the phenotypes of MAFLD in mice, namely hepatocyte injury and ballooning (indicated by H&E staining), hepatic steatosis (indicated by oil red O (ORO) staining), and inflammation (indicated by IL-6 and CD68 examination) (Figure 1g). Notably, this therapeutic effect was not due to the altered feeding behavior (Figure S2A). Gene expression

Read the complete text